Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

Alongside opening the new offices, Roche Diagnostics' capabilities in China have been further recognised as it has been ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

Carolyn Kay, medical affairs lead at Roche Diagnostics, said it’s “exciting” that these tests are now available in the U.S., ...

Data from two Alzheimer’s tests being developed by Roche Holding AG showed high accuracy in detecting the disease in patients being tested for the condition. The tests measure biomarkers in the blood ...

Roche Holding AG (RHHVF) Company Description: Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The ...

Cepheid and Roche Diagnostics Tests Provide Rapid and Decentralized Detection Options as Mpox Cases Continue to Rise ...

Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its ...